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Radioiodine Therapy of Thyroid Disease 
WILLIAM H. BEIERWALTES 
Division of Nuclear Medicine, Department of Internal Medicine, University of Michigan Medical Center, 
Ann Arbor, MI 48109. U.S.A. 
Ten “ideal” steps used at the University of Michigan to treat well-differentiated thyroid cancer are 
presented. Using this in 103 patients with well-differentiated thyroid carcinoma and metastases outside 
their neck, those that were freed of their disease after “‘I therapy 
Introduction 
Many patients with well-differentiated thyroid car- 
cinoma die of their disease. It is the conviction of the 
author that almost no patient with well-differentiated 
thyroid carcinoma need die of his/her disease. 
A review of the literature (Harness et al., 1974) 
shows that 75% of patients with all types of thyroid 
cancer and distant metastases die within 5 years of 
the diagnosis. We have followed this high risk group 
(103 patients with metastases outside their neck from 
well-differentiated thyroid carcinoma) for up to 35 
years to determine the effectiveness of treatment at 
University of Michigan (Beierwaltes et al., 1982). 
The treatment of well-differentiated thyroid cancer 
at our institution has been divided into a ten step 
protocol to assess the rate of conformity to these 
procedures and determine the effect of conformity on 
cure rate. The lack of conformity indicates the pro- 
cedure was not performed because either the patient 
had not been asked to have the procedures, or died 
before the procedures were instituted. 
The 10 “ideal” steps in treatment Vollowed since 
1947) 
1. Thyroidectomy within 1 year of the detection of 
a goiter. 
2. Lobectomy and isthmasectomy with a frozen 
section; if carcinoma is found, an immediate contra- 
lateral lobectomy. 
3. Off oral T4 and T3 post surgery for 6 weeks 
before imaging. 
4. Do radioiodide imaging 6 weeks post surgery. 
5. (a) If significant residual uptake is seen in the 
thyroid bed, treat with 150 mCi of radioiodine to 
ablate the uptake in this “remnant”. 
(b) Treat with 175 mCi of radioiodine if there is 
uptake in the cervical nodes (metastases). 
17 
(c) Treat with 200 mCi (7.4GBq) if there are 
metastases outside the neck. 
6. Administer replacement T4 between check-ups. 
7. Re-check at 1 year post radioiodine treatment 
with the patient off all thyroid hormone for 6 weeks. 
8. If the 1 year scan post treatment radioiodine 
image is negative, re-check in 2 years. 
9. If the 3 year radioiodine image is negative, 
re-check every 5 years thereafter with patient off all 
thyroid hormone for 6 weeks prior to imaging. 
10. If there is recurrence of radioiodine uptake at 
any time we treat with 200mCi of iodine. 
1981 Study 
One hundred and three (103) patients with well- 
differentiated thyroid carcinoma and metastases 
outside their neck were treated using our treatment 
protocol. Those considered free of their metastatic 
disease after “‘I therapy survived three times longer 
than those not cured of their disease. Patients freed 
of their metastases showed better conformity with 
the treatment protocol than those patients not 
demonstrating cure of their metastases. 
Age of the Patient and “Cure” 
Papillary carcinoma 
Those freed of their disease (average age 20) were 
half the age of those with residual cancer (age 45). 
This strongly supports the argument to aggressively 
treat young patients with papillary carcinoma of the 
thyroid while there is still a chance for “cure”. 
Follicular carcinoma 
Those patients successfully freed from their disease 
(average age 36) were about two-thirds the age of 
‘I 
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those not cured of their disease (age 57). Again, this 
is strong evidence that younger patients with follic- 
ular carcinoma should be treated more aggressively 
since “cure” may be possible. 
Leukemia and Second Cancers 
None of the patients developed and/or died from 
leukemia and there was no increased incidence of 
second cancers. These results are in striking contrast 
to the reported 90 to 170-fold increased risk of acute 
leukemia at 2 years post treatment of carcinoma of 
the overy with cancer chemotherapy (Beierwaltes, 
1981; Chabner, 1977). 
Time from Original Surgery 
(Histopathological Diagnosis) 
to First detection of Metastases 
Outside of the Neck 
At the time of the original surgery 39.4% of the 
patients did not have thyroid cancer metastases de- 
tected. The metastases were first detected outside the 
neck 7.44~ after the initial surgery with a range of 
1-25 years. This is an important observation because, 
if inadequate surgery is performed and the patient is 
only followed without ablating the radioiodine up- 
take in the thyroid bed, it cannot be determined if the 
patient has metastases since the metastases will not 
concentrate radioiodine, with rare exceptions, as long 
as significant uptake remains in the thyroid bed. If 
one takes a “conservative” approach and waits until 
the patient demonstrates clinical evidence of cancer 
elsewhere, statistically, the death rate is markedly in- 
creased and the opportunity to eradicate the patient’s 
disease is lost. 
Thus, there is strong evidence that radioiodine 
should be given to ablate any uptake in the thyroid 
bed after adequate surgery since the patient is 
potentially “curable” rather than adopting a 
“conservative” approach of simply following the 
patient. 
Thyroidectomy 
The single most important step in the treatment of 
thyroid cacinoma is a lobectomy and isthmectomy 
followed by a lobectomy of the opposite side if 
carcinoma is found. Cervical nodes from both the 
central chamber and the lateral areas should be 
sampled and if carcinoma is found there should be 
extensive node plucking. This can be done through a 
collar incision. If there is concern about the morbid- 
ity of bilateral lobectomy in the treatment of proven 
carcinoma of the thyroid, one should be aware that 
the only argument raised by the experienced endo- 
crine surgeon when considering the type of surgical 
thyroidectomy for Grave’s disease in children, is 
whether they should perform a 95% thyroidectomy 
or a bilateral total lobectomy. Since this is the only di- 
lemma in the surgical treatment of childhood Grave’s 
disease, it is unclear why a surgeon should be hesitant 
to perform a bilateral lobectomy or isthmectomy to 
treat proven carcinoma of the thyroid. A complete 
and true total thyroidectomy eliminates the need for 
radioiodine therapy and in our experience, is associ- 
ated with a high permanent freedom from disease. 
Surgeons at our institution are convinced that a total 
thyroidectomy may be performed with lower mor- 
bidity (in good hands) than a subtotal lobectomy. In 
a sub-total lobectomy, the laryngeal nerves and para- 
thyroid glands are not as carefully isolated before 
resecting the thyroid tissue. 
Many surgeons find that they achieve a lower 
morbidity with a bilateral total lobectomy for prim- 
ary carcinoma of the thyroid than from a sub-total 
thyroidectomy for Grave’s disease. A residual uptake 
in the neck of less than 5% usually allows staging. 
Another important reason for a double lobectomy 
is that microscopic cancer foci are found in the 
contralateral lobe in 38-87% of patients. Clinical 
occurrence of cancer in the opposite lobe after uni- 
lateral lobectomy is 240%. Recurrence of cancer 
after subtotal thyroidectomy has been shown by 
Mazzaferri to be twice as common than following 
bilateral total lobectomy (Mazzaferri and Young, 
1981). It is also possible that there could be an 
anaplastic focus in the thyroid that when properly 
removed would prevent its progression to a clinically 
anaplastic carcinoma of the thyroid. 
The hazard of recurrences has been documented in 
the literature. Mazzaferri and Young (198 1) reported 
that in a 10 year follow-up of 576 patients there 
were 84 recurrences. All six deaths from carcinoma 
occurred in this group. Nineteen percent of patients 
with recurrences could not have their disease 
eradicated. Deaths in these patients began after 30 
years of age. Cervical lymph node metastases were 
associated with increased recurrence rates. Thus, the 
old statistical myth of the prognosis not being worse 
when cervical lymph node metastases are present is 
incorrect. That myth arose because young people 
commonly have cervical node involvement and do 
well for several years while old people tend not to 
have cervical node involvement and have a shorter 
survival time. 
Maheshwari et al. (1981) in a report of 352 patients 
found 97 patients with recurrent disease. One 
fourth of the patients with recurrent disease failed 
to concentrate radioiodine. Forty-four patients died 
of progressive thyroid carcinoma. All of the patients 
who died were over 40 years of age. 
A delay in treatment may allow recurrence or 
metastases. An image at 6 weeks after surgery allows 
one to institute radioiodine treatment to ablate the 
remnant and treat micrometastases without delay. 
There is evidence in the animal model that delay 
increases the number of lung metastases. Prompt 
adequate surgery and radioiodine therapy allows 
immediate staging. Prompt adequate surgery and 
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radioiodine also insures better compliance on the HTG is higher with bone and lung metastases than 
part of the patients. with lymph node metastases. 
Commonly Asked Questions Concerning 
Therapy of Malignant Thyroid Disease 
1. Does lack of T4 and T3 increase tumor growth 
The only hard data on this subject evolves from 
experiments in animal models. Sisson and Beierwaltes 
(1964) showed that well-differentiated papillary 
carcinoma of the thyroid grew the fastest in the 
euthyroid rat and slowest in the rat kept hypothyroid 
the longest. More recently it has been shown in the 
sarcoma of the Ajax mouse, the Lewis fibrosarcoma 
in C 57BL/60 mice (Kumar et al., 1979) and in 
mammary tumors in mice (Vonderhaar and Greco. 
1982) that these observations are correct. Thus, the 
only controlled experiments indicate that lack of 
thyroid hormone decreases the growth rate of cancer. 
Schneider (1981) showed that 14 of 15 patients with 
thyroid cancer had serum HTG in the normal range 
(less than 10 mg/mL) while on T3. High HTG levels 
did not distinguish residual tissue from metastases 
and HTG levels were greater than normal in 18% of 
patients with negative images. There were positive 
images in 14 out of 32 patients (44%) where the HTG 
was less than 2 mg/mL. The conclusions of this study 
were substantiated by Echenique et al. (1982) and 
indicates that the combination of radioiodine images 
and HTG were better than using either alone. 
6. Why not give 3OmCi (1.11 GBq) of radioiodine 
ablating dose for thyroid remnant rather than 15OmCi 
(5.55GBq)? 
2. Why not continue T4 and give TSH injections? 
Although this was done in the past, it is no longer 
followed in most centers. There is a higher incidence 
of allergic reactions to TSH, the formation of neutral- 
izing antibodies in TSH resistance, a rapid decline 
of serum TSH levels (short blood half-life), and a 
lower tumor uptake of radioiodine (Krishnamurthy 
and Blahd, 1977; Hays et al., 1967: Hershman and 
Edwards, 1972; Gershengorn et al., 1975). 
The original advocates of the use of 29.9mCi 
(1.1 GBq) of 13’1 to ablate uptake in “normal thyroid 
gland remnants” after surgical thyroidectomy, for 
the treatment of well-differentiated thyroid cancer, 
believed that this dose would ablate the uptake in a 
normal remnant (McCowen et al., 1976). Thirty-nine 
percent of their patients whose remnant was not 
ablated with 29.9 mCi (1.1 GBq) and required an 
additional 100 mCi (3.7 GBq) dose at a later time to 
accomplish this, demonstrated thyroid cancer in a 
previously judged “normal” remnant. 
3. Why not withdraw T3for only 2 weeks and decrease 
the period of fatigue and cold intolerance? 
We do not do this because we have had occasional 
patients with metastatic carcinoma of the thyroid to 
lung who did not show uptake of radioactive iodine 
after withdrawal of T3 for as long as 3 weeks but did 
show an excellent uptake for both diagnosis and 
treatment in the lungs when they had been off T3 for 
a period of 6 weeks. 
Two subsequent studies in which patients were 
followed for longer periods to check on the “ablative” 
effects of a 29 mCi (1.1 GBq) dose of 13’1 in normal 
remnants found that a second dose was required in 
12 of 13 patients and 16 of 17 patients respectively 
(Kuni and Klingensmith, 1980; Siddiqui et al., 1981). 
4. Why not use radioactive “‘Tl instead of 13’1 to avoid 
taking the patient of,7 thyroid hormone? 
It has been demonstrated that some patients will 
have their metastases detected with 20’Tl that did not 
concentrate radioiodine. It has also been demon- 
strated that some patients will have their metastases 
detected with *O’Tl as well while they are on thyroid 
hormone (Harada et al., 1980). Following these orig- 
inal observations, abundant evidence has appeared 
from our laboratory and others (Vat-ma et al., 1987) 
that the use of thallium is less reliable than “‘1 since 
it may also image normal lymph nodes. 
Four hundred and sixty-two patients with well- 
differentiated thyroid cancer and “‘I uptake in 
thyroid remnants have been studied at the University 
of Michigan. A 99% follow-up was achieved for a 
period of 15 y (0.2-37.4 y) after the first 13’1 treatment 
(Beierwaltes et al., 1984). Of the 267 patients with 
radioiodine uptake confined to the thyroid bed, 233 
(87%) had ablation from the first dose of 13’1 using 
doses ranging from 100 to 200mCi (3.7-7.4GBq). 
The higher the percent uptake the more difficult it 
was to achieve ablation. The average ablation success 
reported elsewhere from 30 mCi (1.11 GBq) or less is 
approximately 60% (Sisson and Beierwaltes, 1983). 
5. Why not use serum thyroglobulin (HTG) instead of 
the radioiodine uptake? 
The lo&l44 mCi (3.7-5.3 GBq) ablative dose may 
furnish “adjuvant” therapy for occult metastases. 
There is also increasing evidence that a suboptimal 
radiation dose decreases the biologic half-life of 
subsequent radiation doses and therefore decreases 
the chance of curing the patient (Rawson et af., 1951; 
Henk et al., 1972; Benua et al., 1962; Rawson and 
Leeper, 1971). 
There is abundant evidence that the serum HTG is 
increased in many thyroid diseases (Echenique et al., 
1982). It is released from both benign and malignant 
tissue, particularly with an increasing serum TSH. It 
also detects non-functioning metastases. The serum 
7. Why not treat with x-ray therapy instead of 13’1? 
We do not use external beam x-ray therapy before 
radioiodine because it decreases the TliZb of 13’1 in the 
thyroid cancer thus diminishing the effective radi- 
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ation dose from 13’1 (Benua et al., 1962; Rawson and 
Leeper, 1971). It is not effective in treating well- 
differentiated thyroid cancer (Cady, 1979). It does 
not ablate the uptake of “‘I (Carr et al., 1958) and 
it increases the incidence of bone marrow depression 
after 13’1 treatment (Haynie and Beierwaltes, 1963). 
Mazzaferri and Young (1981) showed in their study 
of 576 patients that it adversely effects the outcome. 
Many investigators believe that external beam 
therapy should be used only in the treatment of 
anaplastic carcinoma of the thyroid, adenocarcino- 
mas refractory to 13*1 therapy, lymphoma, and possibly 
in Hurthle cell and medullary thyroid carcinoma. 
8. Why treat young healthy asymptomaticpersons with 
lung metastases and at what dose of radioiodine does 
pulmonary fibrosis occur? 
Rall et al. (1957) showed that less than 100 mCi 
(3.7 GBq) of radioiodine uptake in the lungs will not 
induce subsequent pulmonary fibrosis. Pulmonary 
fibrosis has only resulted when more than 100 mCi 
(3.7 GBq) of lung uptake occurred in patients with 
diffuse bilateral pulmonary metastases. The highest 
percent uptake observed in the lungs at the University 
of Michigan was 35%. Since we never exceed a 
dose of 200mCi (7.4GBq) it has not been possible 
to achieve a 100 mCi (3.7GBq) treatment dose in 
the lungs and therefore we have never produced 
pulmonary fibrosis or deteriorating lung function. 
9. Will “‘I therapy decrease fertility or increase the 
incidence of birth abnormalities? 
Sarkar et al. (1976) followed 40 children treated 
for thyroid cancer, receiving a mean total dose of 
196 mCi (7.25 GBq) and a maximum dose of 691 mCi 
(25.6GBq), for a period of from 1 to 25 y. No 
decreased fertility or abnormal birth history has 
occurred. 
10. Can radioiodine cause anaplastic transformation? 
Mazzaferri and Young (1981) showed that only half 
of the reported patients with papillary and follicular 
thyroid carcinoma who developed anaplastic cancers 
had a documented history of previous irradiation. 
Solid data on anaplastic transformation has not been 
established. 
1 I. What is the recommended radioiodine dose to treat 
malignant thyroid disease and its complications? 
“Standard” doses. A standard adult dose of 
150 mCi (5.55 GBq) of 13’1 for a thyroidal remnant is 
used at the University of Michigan because it has 
proved successful in 87% of patients who have 
received adequate surgery, as discussed above. We 
administer 175 mCi (6.5 GBq) when there is demon- 
strated uptake of ‘)‘I in lymph nodes after extensive 
surgical lymph node plucking. We administer a stan- 
dard adult dose. of 200 mCi (7.4 GBq) for metastases 
outside the neck. Several reasons support this use of 
a “standard” dose of 200mCi (7.4GBq) for adults 
with metastases outside the neck: 
(a) NRC restriction on maximum single total 
dose. In 1956, the Atomic Energy Commission Sub- 
committee on Human Use, began to include in the 13’1 
license a limit of 200 mCi (7.4 GBq) on single doses 
for cancer therapy (Benua et al., 1962). 
(b) The NRC Sub-committee on Human Use sup- 
ported this limit since a study they financed failed to 
establish data that proved that single doses greater 
than 200mCi (7.4GBq) were more effective than a 
200 mCi (7.4 GBq) dose. They also found that doses 
greater than 200 mCi (7.4 GBq) were associated with 
an increased incidence of complications (Benua et al., 
1962). 
(c) Patients who have died from their thyroid car- 
cinoma have received larger total doses than patients 
successfully freed of their metastases (Leeper, 1973; 
Phillips, 1954). 
(d) It has been shown that blood radioiodine doses 
larger than 200 cGy (rad) carry an increased risk of 
complications (primary bone marrow depression) 
and, it is reasonable to do studies that allow a 
calculation of the dose required to deliver a blood 
dose of 200 cGy. 
The reasons we do not administer more than 200 mCi 
(74GBq) are that: 
(i) it requires a minimum of 4 days of patient study 
after administering the tracer dose (Leeper, 1973); 
(ii) the treatment dose frequently exhibits different 
kinetics than the tracer dose (Benua et al., 1962); 
(iii) the proponents of this procedure have demon- 
strated that treatment doses in excess of 200mCi 
(7.4 GBq) carry an increased risk of complications 
(Benua et al., 1962). 
In summary, we urge more adequate surgery and 
‘)‘I ablative therapy in patients under 40 years of age 
and with well-differentiated thyroid cancer while cur- 
able and cessation of 13’1 therapy when the patient 
develops rapidly progressive, less well-differentiated 
and/or hopelessly advanced disease. It is our feeling 
that this approach is more conservative than in- 
adequate surgery or inadequate “‘1 therapy when the 
disease is curable; and reserve aggressive therapy only 
when the disease is incurable. 
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